Getinge AB (GNGBY)
OTHER OTC:GNGBY
Want to see GNGBY full AI Analyst Report?
GNGBY Stock Chart & Stats
$22.97
$0.02(0.10%)
At close: 4:00 PM EST
$22.97
$0.02(0.10%)
Day’s Range― - ―
52-Week Range$18.88 - $24.82
Previous CloseN/A
Volume7.12K
Average Volume (3M)149.00
Market Cap
$5.48B
Enterprise Value$58.68B
Total Cash (Recent Filing)$4.02B
Total Debt (Recent Filing)$10.99B
Price to Earnings (P/E)22.4
Beta0.72
Next Earnings
Jul 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.05%
Share Statistics
EPS (TTM)8.63
Shares Outstanding254,152,370
10 Day Avg. Volume133
30 Day Avg. Volume149
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.02
Price to Sales (P/S)1.70
P/FCF Ratio23.97
Enterprise Value/Market Cap10.70
Enterprise Value/Revenue1.73
Enterprise Value/Gross Profit3.80
Enterprise Value/Ebitda9.56
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue MixA two‑thirds recurring revenue mix creates durable, predictable cash flows and higher effective margins versus one‑time equipment sales. This installed‑base driven model cushions cyclicality in hospital capital spending, supports margin stability, and enables profitable cross‑sell and service growth over multiple years.
Strong Cash Generation & LeverageRobust FCF and modest leverage give Getinge financial flexibility to fund quality remediation, R&D, and selective investments without straining liquidity. Low adjusted leverage versus internal thresholds preserves optionality for capex, M&A or dividend continuity, supporting long‑term operational resilience.
Regulatory & Product MilestonesRecent CE approvals and product launches expand addressable markets and reinforce competitive positioning in ECLS, vascular grafts and life‑science sterilization. Regulatory clearances and new equipment sustain multi‑year adoption, recurring consumable demand and strengthen the product pipeline for durable growth.
Bears Say
Elevated Quality‑Related CostsPersistently high quality remediation costs materially depress margins and divert cash and management focus from growth initiatives. Even with a targeted reduction, multi‑year remediation schedules can compress returns on invested capital and slow margin recovery toward long‑term targets.
Currency & Tariff HeadwindsMeaningful FX and tariff impacts reduce reported profitability and complicate forward planning. If trade barriers or unfavorable currency trends persist, pricing power may be limited and margins squeezed, forcing structural cost actions or sustained price increases that can impair competitiveness.
ACT Weakness & Softer Top‑LineWeakness in Acute Care Therapies and softer organic revenue (TTM down ~2.5%) signal pockets of demand erosion. Slower top‑line momentum makes it harder to hit 2028 margin goals without deeper restructuring, and may require heavier trade‑offs between investment in growth and near‑term profitability restoration.
Getinge AB News
GNGBY FAQ
What was Getinge AB’s price range in the past 12 months?
Getinge AB lowest stock price was $18.88 and its highest was $24.82 in the past 12 months.
What is Getinge AB’s market cap?
Getinge AB’s market cap is $5.48B.
When is Getinge AB’s upcoming earnings report date?
Getinge AB’s upcoming earnings report date is Jul 17, 2026 which is in 41 days.
How were Getinge AB’s earnings last quarter?
Getinge AB released its earnings results on Apr 21, 2026. The company reported $0.161 earnings per share for the quarter, beating the consensus estimate of N/A by $0.161.
Is Getinge AB overvalued?
According to Wall Street analysts Getinge AB’s price is currently Overvalued.
Does Getinge AB pay dividends?
Getinge AB pays a Annually dividend of $0.478 which represents an annual dividend yield of 2.05%. See more information on Getinge AB dividends here
What is Getinge AB’s EPS estimate?
Getinge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Getinge AB have?
Getinge AB has 254,152,370 shares outstanding.
What happened to Getinge AB’s price movement after its last earnings report?
Getinge AB reported an EPS of $0.161 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.435%.
Which hedge fund is a major shareholder of Getinge AB?
Currently, no hedge funds are holding shares in GNGBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Getinge AB Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.55%
12-Months-Change
Fundamentals
Return on Equity
7.97%
Trailing 12-Months
Asset Growth
1.50%
Trailing 12-Months
Company Description
Getinge AB
Getinge AB is a global medical technology company based in Sweden, specializing in advanced solutions for healthcare professionals in the hospital and life sciences sectors. The company operates primarily in three areas: Surgical Workflows, Critical Care, and Life Science. Getinge's core products include surgical instruments, sterilization systems, intensive care unit equipment, and biopharmaceutical manufacturing solutions, aimed at improving patient outcomes and enhancing operational efficiency in healthcare facilities.
GNGBY Company Deck
GNGBY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of constructive operational and financial developments — organic sales growth, stronger order intake, important product approvals (Cardiohelp II CE) and solid cash/financial metrics — alongside material near-term headwinds from currency and tariffs, continued elevated quality-related costs in transition, and softness in Acute Care Therapies (notably ventilators). Management reiterated 2026 top-line guidance (3%–5% organic growth adjusted for surgical perfusion phaseout) and the long-term margin ambition (16%–19% by 2028) while withholding margin guidance for 2026 due to uncertainty. Overall, the positive operational momentum, strong cash flow and strategic product wins slightly outweigh the near-term margin and geopolitical challenges.View all GNGBY earnings summariesTechnical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---